Skin Cancer Treatment Selection: Mohs, Excision, Radiation, and Nonsurgical Care — A Living Review

Start With the Diagnosis and the Decision

The phrase skin cancer treatment hides several different clinical problems. A superficial basal cell carcinoma on the trunk, a recurrent infiltrative BCC on the nose, a deeply invasive cutaneous squamous cell carcinoma with perineural symptoms, and a 1.8-mm melanoma are not variations of one disease. They differ in patterns of extension, metastatic potential, staging requirements, useful margin methods, and systemic-treatment pathways.^1–6

Before selecting a procedure, establish the exact diagnosis, biologic risk, clinical extent, relevant anatomy, patient health, and goal of care; those inputs define the treatment problem.

1. What exactly did the biopsy establish?
2. Which features change local recurrence, nodal risk, or distant-spread risk?
3. Does the treatment need sampled margins, complete margin assessment, microstaging, or nodal staging?
4. What tissue, function, or future reconstruction is at stake?
5. What treatment burden and risk are reasonable for this patient?
6. How will success and recurrence be assessed over time?

A visually small tumor can carry a large margin problem. A broad superficial lesion can carry a small metastatic risk but a meaningful treatment-burden problem. A frail patient can rationally choose a different balance than a healthy younger patient with the same biopsy label. The treatment plan should be specific enough to explain those differences without pretending that one modality is universally superior.

Risk Stratification and Staging Do Different Jobs

Risk stratification estimates how a tumor is likely to behave and helps select local treatment. Staging estimates how far the disease has extended and helps determine prognosis, imaging, nodal evaluation, and systemic management. They overlap, but they are not interchangeable.^2,3,5

For BCC, treatment risk is shaped by location, size, border definition, primary versus recurrent status, histologic growth pattern, perineural involvement, immune status, and prior radiation.^1,4 Distant spread is rare, so the dominant concerns are local control, tissue preservation, and avoidance of destructive recurrence.

For cSCC, the same local factors matter, but depth, differentiation, perineural or lymphovascular invasion, invasion beyond subcutaneous fat, bone involvement, rapid growth, and immune suppression can move the discussion toward nodal evaluation, imaging, adjuvant radiation, or systemic therapy.^2,5,7

For melanoma, Breslow thickness and ulceration drive the primary-tumor category and influence excision margins, sentinel-node discussion, stage, and systemic therapy.^3,6 A margin method that is appropriate for keratinocyte cancer cannot be imported into melanoma without accounting for permanent-section microstaging and melanocytic immunostains.

Margin Assessment Is a Treatment Variable

A treatment cannot be compared fairly without asking how the margin is assessed.

In standard excision, the tumor is removed with a planned clinical margin and the specimen is usually evaluated in representative vertical sections. This is effective and appropriate for many well-defined tumors. It does not examine every millimeter of the peripheral and deep margin.^8,9

In Mohs surgery, the excised layer is mapped and processed so that the peripheral and deep margins can be examined as a continuous en-face surface. Additional tissue is removed only where tumor remains. This feedback loop is particularly useful for recurrent, poorly defined, aggressive, or anatomically constrained tumors.^8–11

During the wait between Mohs stages, the tissue layer is oriented, processed, stained, examined, and mapped before the next decision. Complete margin assessment is not synonymous with “more surgery”; it is more information during surgery. That information can reduce the need to take a wide empirical margin, identify unexpected extensions, and establish clearance before a flap or other major tissue rearrangement.^9–12

For melanoma in situ and selected early invasive melanomas in constrained sites, staged excision or immunostain-assisted Mohs can provide complete peripheral margin assessment. The central tumor still needs appropriate permanent-section evaluation for microstaging; standard frozen sections without melanocytic immunostains are not interchangeable with that pathway.^3,6,13

Choosing Among Surgical Treatments

Mohs surgery

Mohs is usually most compelling when one or more of the following are present:

• high-stakes anatomy where tissue preservation changes function or reconstruction;
• a recurrent tumor or one arising in scarred or previously irradiated skin;
• aggressive, mixed, or poorly defined growth;
• perineural involvement or another feature that makes extension harder to predict;
• immune suppression or a higher-risk cSCC pathway;
• a large tumor, indistinct border, or mismatch between the visible lesion and the biopsy;
• a need to confirm clearance before major reconstruction.^1,2,8–12

The best randomized evidence is in facial BCC. At 10 years, Mohs had a statistically significant recurrence advantage for recurrent facial BCC; the primary-BCC difference favored Mohs but did not reach statistical significance in that trial.¹⁰ Observational studies and systematic reviews generally support lower recurrence with complete margin assessment in higher-risk keratinocyte cancers, but patient selection and tumor mix limit simple universal cure-rate claims.^11,14,15

Standard excision

Standard excision remains an excellent treatment for many primary, well-defined BCCs and cSCCs when an appropriate margin can be removed without unacceptable functional or reconstructive cost.^1,2,4 It is also the standard operation for most localized invasive melanomas, using margins based on Breslow thickness.^3,6

The pathology request and reconstruction plan should match risk. For higher-risk keratinocyte cancers, major tissue rearrangement should generally wait until clear margins are established.^1,2,12

Other surgical approaches

Deep shave removal, curettage, and electrodesiccation occupy a different part of the spectrum. Curettage and electrodesiccation best fit carefully selected primary, well-defined, lower-risk keratinocyte cancers in appropriate sites, but they do not provide the same margin information as an oriented excision or Mohs layer.^16–18

When Nonsurgical Local Treatment Fits

Nonsurgical treatment is not one category. Topical imiquimod, topical fluorouracil, photodynamic therapy, cryotherapy, and observation differ in evidence, indications, treatment burden, inflammation, recurrence, and ability to confirm clearance.

For superficial BCC, Jansen et al.'s five-year head-to-head trial reported tumor-free survival of 80.5% with imiquimod, 70.0% with topical 5-fluorouracil, and 62.7% with photodynamic therapy.¹⁹ Surgery generally provides higher long-term tumor-free rates in its studied settings. Topical therapy treats a field but does not yield a complete margin specimen. It should not be treated as a substitute for margin-controlled surgery in a recurrent, infiltrative, micronodular, morpheaform, poorly defined, or otherwise higher-risk BCC.^1,4,19,20

For SCC in situ, topical or destructive treatment can fit selected lesions. That logic should not be silently extended to invasive cSCC, where depth and adverse histology may be incompletely sampled and where local failure can carry greater consequence.^2,5

Observation can be reasonable for a narrow group of patients when tumor growth is expected to be slow, life expectancy or competing illness changes the value of intervention, and follow-up is reliable.²¹ Observation is an active plan with a trigger to reconsider—not abandonment of care.

Radiation Therapy

Radiation can be used as definitive treatment when surgery is not feasible or is declined after informed counseling, and as adjuvant treatment for selected tumors with features that create concern beyond what local surgery alone addresses.^1,2,22

It solves the margin problem differently from surgery. Radiation treats the tumor and a planned surrounding field in place. There is no excised specimen proving microscopic clearance; success is assessed clinically over time. Treatment commonly requires multiple visits, and acute reactions can include erythema, crusting, and discomfort. Late effects can include pigment change, telangiectasia, atrophy, fibrosis, hair loss, and a skin field that may be more difficult to re-treat or reconstruct.^22–24

The strongest randomized comparison of surgery and radiotherapy for facial BCC favored surgery for local control and long-term cosmesis, but it studied older radiation techniques and should not be used as if it were a modern randomized trial of image-guided superficial radiation versus Mohs.^23,24 Contemporary image-guided superficial-radiation studies report high short-term control in selected cohorts, but the literature is predominantly retrospective, uses heterogeneous definitions, and lacks a direct modern randomized Mohs comparison. Those limitations belong in the consent discussion.

Radiation is not “no scar.” It creates a different pattern of tissue change. Nor is surgery always the right choice. A patient who cannot safely undergo surgery, cannot tolerate a complex reconstruction, or makes an informed preference for radiation may reasonably choose it.

Disease-Specific Treatment Pathways

Basal cell carcinoma

Many low-risk BCCs can be treated effectively with standard excision, curettage, or—in carefully selected superficial disease—topical therapy. Mohs is usually favored when recurrence, aggressive histology, indistinct borders, high-stakes anatomy, or tissue preservation changes the consequence of residual tumor.^1,4,10,19

Locally advanced BCC that cannot be managed reasonably with local surgery or radiation may enter a hedgehog-inhibitor or immunotherapy pathway, often with multidisciplinary input.^25–27

Cutaneous squamous cell carcinoma

Lower-risk cSCC can be treated with standard excision and, in narrowly selected circumstances, destructive treatment. Higher- and very-high-risk disease benefits from deliberate margin strategy, assessment of nerves and regional nodes, and consideration of imaging, radiation, or systemic therapy.^2,5,7,14

For selected advanced cSCC, PD-1 therapy has changed the systemic-treatment pathway. It does not replace adequate risk assessment or local control planning.²⁸

Melanoma

Most localized invasive melanoma is treated with wide local excision using a thickness-based clinical margin. Sentinel-node biopsy is discussed when the probability of nodal disease is high enough to make staging information useful. Selected melanoma in situ or minimally invasive disease in constrained sites may be managed with staged margin control by an experienced team.^3,6,13

Node-positive, resectable stage III, high-risk resected, or metastatic melanoma belongs in a multidisciplinary pathway that may include immunotherapy or targeted therapy. The local margin operation is only one part of that care.^6,29,30

Urgency and Sequencing

Most skin cancers require timely treatment, but not every diagnosis is a medical emergency. A planned short interval used to obtain pathology, coordinate medicines, or select an appropriate team is different from indefinite deferral.

Features that should accelerate review include rapid growth, pain, numbness, tingling, weakness, fixation, bleeding, ulceration, aggressive pathology, immune suppression, threatened eye or other function, palpable nodes, recurrent disease, or concern for spread.^2,3,5,7

Delay can enlarge a surgical defect even when it does not change stage.³¹ For biologically aggressive cSCC or melanoma, progression can change staging and treatment options. For a small low-risk BCC, a short coordinated delay may carry much less consequence. The article should therefore state the decision deadline—days, weeks, or a planned interval—rather than simply label every case urgent or nonurgent.

Shared Decision-Making Without False Equivalence

Shared decision-making does not mean presenting every option as equally effective for every tumor. It means stating the medically reasonable options, the evidence behind each, the important uncertainties, and the tradeoffs that matter to the patient.

A useful discussion includes:

• how the diagnosis and risk category were established;
• whether the procedure provides complete, sampled, or no histologic margin assessment;
• expected number of visits and treatment duration;
• likely repair and functional consequences;
• acute and late adverse effects;
• what happens if the first treatment fails;
• how recurrence will be detected; and
• whether health, transportation, caregiving, or personal priorities change the balance.

Related Patient Guides

The linked Patient Journey guides translate this framework into the next practical question after diagnosis.